“In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations…”
Articles about “breakthrough therapies” are often useless to the newly diagnosed cancer patient primarily because if you have just been diagnosed with a cancer as aggressive as pancreatic cancer you need effective therapy now. Not years from now.
However, the article linked and excerpted below mentioned two key findings that are useful now to pancreatic cancer patients. According to the article below, Triphendiol:
slows tumor growth and sensitizes tumors to chemotherapy treatments
is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations…
If the newly diagnosed pancreatic cancer patient is not eligible for whipple surgery then he/she faces long odds. I am a survivor of an “incurable” cancer as well. I also faced long odds. Back in 9/97 when my conventional oncologist told me that “we can do nothing more for you.“
Please consider non-conventional therapies such as triphendiol, curcumin and resvertrolin conjunction with low doses of conventional chemotherapy regimens such as gemcitabine.
Please take a moment to watch the short video below in order to learn more about some of these therapies:
Cholangiocarcinoma is a medical term denoting a form of cancer that is composed of mutated epithelial cells (or cells showing characteristics of epithelial differentiation) that originate in the bile ducts which drain bile from the liverinto the small intestine. Other biliary tract cancers include pancreatic cancer, gallbladder cancer, and cancer of theampulla of Vater.
Cholangiocarcinoma is a relatively rare neoplasm that is classified as an adenocarcinoma (a cancer that forms glands and/or secretes significant amounts of mucins). It has an annual incidence rate of 1–2 cases per 100,000 in the Western world, but rates of cholangiocarcinoma have been rising worldwide over the past several decades.
“Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines,slows tumor growth and sensitizes tumors to chemotherapy treatments. Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pre-treating the cell lines with triphendiol increased the effectiveness of chemotherapy. Animal model studies showed that triphendiol in combination with chemotherapy inhibited tumor growth more effectively than each drug alone.
“In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations,” Tytler said.
Tytler said that there is an urgent need for new pancreatic cancer treatments because fewer than 20 percent of patients are candidates for surgery. Current treatment is limited to chemotherapy, which is not always effective, as most tumors are resistant to or become resistant to the commonly used chemotherapy drug for pancreatic tumors, gemcitabine…
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
[…] Experimental Biliary Cancer / Pancreatic Cancer Therapy […]Reply